Table 3 Uni- and multi-variable analysis for overall survival
Variable | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | p-Value | HR | 95% CI | p-Value | |
HER2DX ERBB2 score high vs low/med | 0.26 | 0.13–0.49 | <0.001 | 0.40 | 0.17–0.85 | 0.018 |
HER2 IHC 3+ vs others | 0.24 | 0.12–0.44 | <0.001 | 0.47 | 0.21–1.07 | 0.072 |
Hormone receptor status (HR+ vs HR−) | 1.28 | 0.67–2.45 | 0.46 | NA | NA | NA |
De novo metastasis vs relapsed | 0.86 | 0.46–1.60 | 0.626 | NA | NA | NA |
Bone only disease | 0.52 | 0.19–1.47 | 0.217 | NA | NA | NA |
Visceral metastasis | 2.50 | 1.05–5.95 | 0.039 | 1.50 | 0.58–3.88 | 0.410 |
Brain metastasis | 2.40 | 1.18–5.05 | 0.016 | 2.40 | 1.08–5.35 | 0.032 |
Metastatic sites ≥3 vs <3 | 2.80 | 1.50–5.24 | 0.001 | 1.60 | 0.74–3.29 | 0.244 |
